Company Overview and News

 
Valeant: The Xifaxan Killer Could Arrive In November

11h seekingalpha
Cosmo Pharmaceuticals announced that the FDA has set a PDUFA date of November 16, 2018, to decide on its NDA for Rifamycin.

 
Bigger Is Not Always Better

2018-05-22 seekingalpha
For executives, there are a lot of benefits, both real and perceived, to achieving greater scale.

1
5
Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.

 
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-11 sec.gov
UNITED STA

 
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-09 sec.gov
UNITED STA

 
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-09 sec.gov
UNITED STATES

1
Krystal Biotech: Important Catalyst And Value Inflection Point Approaching

2018-05-08 seekingalpha
Entering a value inflection point over the summer. If Krystal Biotech's first clinical product is successful, there is several-fold upside to the current share price.

2
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-04 sec.gov
UNITED STATES

1
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-03 sec.gov
UNITED STA

1
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-02 sec.gov
UNITED STATES

 
SHPG / Shire Plc. FORM 8-K (Current Report)

2018-05-01 sec.gov
UNITED STA

2
The Takeda-Shire Deal: Potential Impact On Neuroscience

2018-05-01 seekingalpha
Takeda has a proposed offer to purchase Shire for approximately $64 billion in cash and stock.

 
SA Interview: M&A And Event-Driven Investing With Masbro Advisors

2018-04-29 seekingalpha
How to evaluate a merger arb idea, where the implied odds of a pending deal are too low (or high) and game-planning different scenarios for how a target will react if a deal doesn’t go through are topics discussed.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 82481R106